Dive into the latest breakthroughs in neurosurgery as we explore the intriguing link between Tyrosine Kinase Inhibitor-induced cerebrovascular occlusion and Moyamoya Disease-like stenosis of the Circle of Willis, shedding light on a critical area of patient care and treatment innovation.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Tyrosine Kinase Inhibitor-induced Cerebrovascular Occlusion Presenting with Moyamoya Disease-like Stenosis of the Circle of Willis.
Terakawa et al., Intern Med 2024
<!– DOI: 10.2169/internalmedicine.3337-23 //–>
https://doi.org/10.2169/internalmedicine.3337-23
This case report highlights a unique adverse effect of tyrosine kinase inhibitors (TKIs), which are used in treating chronic myeloid leukemia (CML). Specifically, it documents a patient with CML who experienced cerebrovascular occlusion of the circle of Willis during TKI therapy, without meeting the diagnostic criteria for moyamoya disease due to the lack of significant moyamoya vessel development. This observation suggests that the suppression of tyrosine kinases, which are crucial for angiogenesis, by TKIs could explain the absence of moyamoya vessel formation. This case underscores cerebrovascular occlusion of the circle of Willis, with minimal moyamoya vessel development, as a potentially important phenotype of TKI-associated vasculopathy. This finding contributes to our understanding of the vascular side effects of TKIs and underscores the need for awareness of such complications in patients undergoing TKI therapy for CML.